Back

The prognostic role of regular NT-proBNP measurement after a rapid-up titration programme of guideline-directed medical therapy in heart failure: essential or superfluous?

9 May 2026 (10:30 - 11:00)
Organised by: Logo
Congress Presentation Part of: Optimisation strategies in heart failure treatment Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Balazs Muk

Gottsegen National Cardiovascular Center, Budapest (Hungary)

3 More presentations in this session

Presentation thumbnail
Healthcare utilisation and clinical outcomes following implementation of an accelerated treatment pathway for patients with HFrEF.
Mrs M. Copley (Auckland, NZ)
Abstract Slides Video
Presentation thumbnail
The effect of increase in NT-proBNP on the efficacy and safety of a rapid up-titration of guideline-directed medical therapy in patients with low predischarge NT-proBNP
Doctor J. Papp (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Patient self-adjustment of diuretics in heart failure: evidence gaps despite guideline recommendations - insights from a scoping review
Ms E. O'Donoghue (Dublin, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Optimisation strategies in heart failure treatment

The Event

Event poster

Heart Failure 2026

9 May 2026 10:30 CET
You may be interested in
thumbnail
Congress Presentation
The effect of increase in NT-proBNP on the efficacy and safety of a rapid up-titration of guideline-directed medical therapy in patients with low predischarge NT-proBNP
thumbnail
Congress Presentation
Clinical Implications of NT-proBNP trajectory following Sacubitril/Valsartan initiation
thumbnail
Congress Presentation
Prognostic role of NT-proBNP in the era of guideline directed medical therapy (GDMT) clinic

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources